Phase II trial of ponatinib in patients with bevacizumab‐refractory glioblastoma
Author:
Affiliation:
1. Dana‐Farber/Brigham and Women's Cancer Center Boston Massachusetts
2. Harvard Medical School Boston Massachusetts
3. Massachusetts General Hospital Boston Massachusetts
Funder
Takeda Oncology
Publisher
Wiley
Subject
Cancer Research,Radiology Nuclear Medicine and imaging,Oncology
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.2505
Reference25 articles.
1. Lomustine and Bevacizumab in Progressive Glioblastoma
2. Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma
3. New Directions in Anti-Angiogenic Therapy for Glioblastoma
4. A phase II trial of AZD2171 (cediranib), an oral pan‐VEGF receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma;Batchelor T;J Clin Oncol,2007
5. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors
Cited by 25 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. A new perspective on antiangiogenic antibody drug resistance: Biomarkers, mechanisms, and strategies in malignancies;Drug Development Research;2024-09
2. Advanced tumor electric fields therapy: A review of innovative research and development and prospect of application in glioblastoma;CNS Neuroscience & Therapeutics;2024-05
3. Status of alternative angiogenic pathways in glioblastoma resected under and after bevacizumab treatment;Brain Tumor Pathology;2024-04
4. Crosstalk between glioblastoma and tumor microenvironment drives proneural–mesenchymal transition through ligand-receptor interactions;Genes & Diseases;2024-03
5. Small Molecule Tyrosine Kinase Inhibitors (TKIs) for Glioblastoma Treatment;International Journal of Molecular Sciences;2024-01-23
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3